Litigation

Recent Posts

AstraZeneca Paying $68.5 Million In Seroquel Settlement
Posted on 12 Mar 2011 by LexisNexis Litigation Resource Community Staff

WASHINGTON, D.C. - (AP) AstraZeneca will pay $68.5 million as part of a multistate settlement over allegations that the drug developer promoted its blockbuster psychiatric drug Seroquel for insomnia, Alzheimer's and other unapproved uses. The New... Read More

Arkansas Judge Orders J&J Unit To Pay $1.1 Billion Penalty For Risperdal Marketing
Posted on 12 Apr 2012 by Tom Moylan

LITTLE ROCK, Ark. - (Mealey's) An Arkansas state court judge on April 11 assessed a $1.1 billion penalty against the Ortho-McNeil-Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson for thousands of violations of state trade practice... Read More

Johnson & Johnson, 2 Units Plead Guilty, Pay $2.2 Billion In Criminal, Civil Penalties
Posted on 4 Nov 2013 by Tom Moylan

WASHINGTON, D.C. — (Mealey’s) Two Johnson & Johnson subsidiaries have pleaded guilty, and the parent company and two subsidiaries will pay $2.2 billion in criminal fines, civil penalties and forfeitures in one criminal and several civil... Read More

South Carolina Judge: $327 Million Penalty Due For Marketing Of Risperdal
Posted on 6 Jun 2011 by Tom Moylan

SPARTANBURG, S.C. - (Mealey's) A South Carolina state court judge on June 3 ordered the Ortho-McNeil-Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson to pay $327,073,700 for violating the state's Unfair Trade Practices Act by using... Read More

La. Supreme Court Reverses $330M Verdict For Risperdal Medicaid Law Violations
Posted on 29 Jan 2014 by Tom Moylan

NEW ORLEANS — (Mealey’s) In a 4-3 vote, the Louisiana Supreme Court on Jan. 28 reversed a verdict of more than $330.6 million against Janssen Pharmaceutical Inc. and parent company Johnson & Johnson, finding that the state attorney general... Read More

Arkansas High Court Reverses $1.2B Risperdal Verdict For State Law Violations
Posted on 21 Mar 2014 by Tom Moylan

LITTLE ROCK, Ark. — (Mealey’s) In a 4-3 decision, the Arkansas Supreme Court on March 20 reversed a $1.2 billion verdict against Janssen Pharmaceuticals for violating state law in its marketing of the antipsychotic drug Risperdal ( Ortho-McNeil... Read More

Texas Risperdal Trial Ends When Janssen Settles For $158 Million, Company Says
Posted on 19 Jan 2012 by Tom Moylan

AUSTIN, Texas -- Johnson & Johnson subsidiary Janssen LLP said Jan. 19 that it has agreed to pay $158 million to settle claims by Texas that it defrauded the Medicaid program through its off-label promotion of the atypical antipsychotic drug Risperdal... Read More

N.J. Risperdal Jury Finds Diabetes Warning Lacking, But Drug Didn't Cause Disease
Posted on 17 Feb 2012 by Tom Moylan

NEW BRUNSWICK, N.J. - (Mealey's) A Risperdal personal injury trial ended Feb. 16 in a defense verdict for Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. after a New Jersey state court jury found that Janssen failed to warn about the... Read More

AstraZeneca Pays States $68.5M For Off-Label Marketing Of Seroquel Antipsychotic
Posted on 11 Mar 2011 by Tom Moylan

TRENTON, N.J. - (Mealey's) AstraZeneca Pharmaceuticals L.P. and AstraZeneca L.P. on March 10 agreed to pay $68.5 million to 37 states and the District of Columbia to resolve allegations in a New Jersey state court lawsuit that it marketed its atypical... Read More

Pa. Risperdal Off-Label Trial Ends With Nonsuit For Janssen
Posted on 14 Jun 2010 by Tom Moylan

PHILADELPHIA - (Mealey's) A Pennsylvania state court judge on June 14 granted Janssen Pharmaceutica Inc.'s motion for a nonsuit of the state government's third-party payer suit alleging that the drug company's off-label marketing of its... Read More